NVision Imaging develops MRI polarizers and hyperpolarized imaging agents that enable metabolic MRI. Its NVision Polarizer uses a parahydrogen-induced polarization (PHIP) technique, applying advances in quantum physics, chemistry, and engineering to deliver fast, robust, and easy-to-use polarization in the MRI setting. The technology aims to detect early metabolic changes at the cellular level, potentially revealing treatment response within days rather than months. NVision planned preclinical use in 2023 and intends to deploy systems for human care in the coming years, targeting installations at over 50 leading cancer centers by 2025. The company has a partnership with Siemens Healthineers and a signed collaboration with Memorial Sloan Kettering to support clinical deployment. Financially, NVision closed a $30M Series A and secured additional government funding to support its clinical advancement.

Total raised

$50M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2023